Nautilus Biotechnology Hires Proteomics Veteran Amber Faust to Lead Sales as Voyager Platform Launches — Nautilus Biotechnology, Inc.

Event summary

Nautilus Biotechnology appointed Amber Faust as Vice President of Sales on March 2, 2026.
Faust brings nearly 20 years of commercial leadership experience in proteomics, including roles at Olink Proteomics, SomaLogic, and Waters Corporation.
The hire follows the public debut of the Nautilus Voyager™ Platform and the launch of the Iterative Mapping Early Access Program.
Faust will lead the commercial launch of Voyager in late 2026, including securing pre-orders and managing instrument installations.
The Nautilus Tau Proteoforms assay is already in use at the Buck Institute for Research on Aging.

The big picture

Nautilus Biotechnology's appointment of Amber Faust as Vice President of Sales marks a critical step in scaling its Voyager Platform, which aims to revolutionize proteomics with single-molecule analysis. The hire underscores the company's push toward commercialization, following the platform's debut and early access program launch. The proteomics field has long struggled with limitations in coverage and resolution, and Nautilus's technology could disrupt the market if it delivers on its promises. The success of this commercial push will hinge on Faust's ability to secure pre-orders and expand market reach, particularly in high-value sectors like drug development.

What we're watching

Commercial Execution: Whether Amber Faust can accelerate the adoption of the Voyager Platform across pharmaceutical, biotechnology, academic, clinical, and government sectors.
Market Differentiation: How Nautilus's single-molecule proteome analysis will compete against established proteomics technologies.
Technological Validation: The pace at which the Voyager Platform gains validation through real-world applications, particularly in neurodegenerative disease research.